Theriva Biologics (TOVX) Return on Capital Employed (2011 - 2026)
Theriva Biologics (TOVX) posted quarterly Return on Capital Employed of 77.78% for Q1 2026, up 2130.0% year-over-year from 3.49% in Q1 2025, and up 20.7% quarter-over-quarter from 98.08% in Q4 2025.
Theriva Biologics (TOVX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Return on Capital Employed for 16 consecutive years, with 77.78% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2130.0% year-over-year to 77.78%; the TTM figure through Mar 2026 stood at 77.78% (up 2130.0% YoY), while the FY2025 annual figure was 89.8%, down 1992.0% from the prior year.
- Return on Capital Employed rose to 77.78% in Q1 2026 per TOVX's latest filing, from 98.08% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.27% in Q1 2022 and bottomed at 138.95% in Q2 2025.
- Historically, Return on Capital Employed has averaged 63.63% across 5 years, with a median of 47.09% in 2024.
- Annual changes were most pronounced in 2025 — Return on Capital Employed sank 7614 bps — and 2026, when it soared 2130 bps.
- Theriva Biologics' Return on Capital Employed stood at 32.01% in 2022, then declined by 30 bps to 41.5% in 2023, then sank by 111 bps to 87.4% in 2024, then decreased by 12 bps to 98.08% in 2025, then rose by 21 bps to 77.78% in 2026.
- Business Quant data shows TOVX's Return on Capital Employed at 77.78% in Q1 2026, 98.08% in Q4 2025, and 118.98% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -48.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.79% |
| Mar 31, 2026 | -77.78% |
| Dec 31, 2025 | -98.08% |
| Sep 30, 2025 | -118.98% |
| Jun 30, 2025 | -138.95% |
| Mar 31, 2025 | -99.08% |
| Dec 31, 2024 | -87.40% |
| Sep 30, 2024 | -82.49% |
| Jun 30, 2024 | -62.81% |
| Mar 31, 2024 | -47.09% |
| Dec 31, 2023 | -41.50% |
| Sep 30, 2023 | -41.15% |
| Jun 30, 2023 | -40.50% |
| Mar 31, 2023 | -36.74% |
| Dec 31, 2022 | -32.01% |
| Sep 30, 2022 | -29.34% |
| Jun 30, 2022 | -24.61% |
| Mar 31, 2022 | -23.27% |
| Dec 31, 2021 | -20.63% |
| Sep 30, 2021 | -15.26% |